Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 43063-371

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 43063-371). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063371 Label (43063371)

Clopidogrel Bisulfate 75 mg film-coated tablets, 30-count prescription drug label by PD-Rx Pharmaceuticals, Inc. The label includes the NDC 43063-371-30, dosage warning, lot number C22E05, and expiration date 09/2023. Information is presented bilingually in English and Spanish, with instructions for use left blank.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01

Chemical structure of Clopidogrel Bisulfate, showing its molecular arrangement including a thiophene ring, bicyclic core, and benzene ring with a chlorine substituent, along with a sulfate group (H2SO4).*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel Bisulfate. The x-axis represents the change relative to clopidogrel tablets administered alone, ranging from 0.4 to 1.4. The chart compares four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with mean values and 90% confidence intervals for each.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03

A line graph showing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over a 12-month follow-up period. It compares two groups: Placebo (+ aspirin) and Clopidogrel bisulfate (+ aspirin), with the latter group showing a lower cumulative event rate. The graph includes a statistical significance value (P=0.00009).*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04

A hazard ratio forest plot figure for patient baseline characteristics and on-study concomitant medications/interventions from the CURE study. The graph shows subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous MI, and previous stroke, comparing Clopidogrel and placebo groups with hazard ratios and confidence intervals.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05

A forest plot chart depicting hazard ratios (with 95% confidence intervals) for patient baseline characteristics and concomitant medications in the CURE Study comparing Clopidogrel versus placebo. Subgroups include Heparin/LMWH, Aspirin dosage groups, GPIIb/IIIa antagonist use, Beta-Blocker use, and Ace Inhibitor use, along with overall data. The x-axis shows hazard ratio values ranging approximately from 0.3 to 1.4 to indicate favoring Clopidogrel or placebo.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06

A line chart titled 'Cumulative Event Rates for Death in the COMMIT Study,' showing percent dead before first discharge over days since randomization (up to 28 days). Two curves compare Placebo (8.1% deaths) and Clopidogrel (7.5% deaths), indicating a 7% proportional risk reduction with Clopidogrel (p=0.03). A note states all treated patients received aspirin.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07

A Kaplan-Meier curve showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares events for placebo and Clopidogrel groups, indicating a 9% proportional risk reduction with Clopidogrel (p=0.002). All patients received aspirin.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08

A forest plot showing the effects of adding Clopidogrel Bisulfate to aspirin on the combined primary endpoint across baseline and concomitant medication subgroups from the COMMIT study. It compares odds ratios with 99% confidence intervals for various subgroups, including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, favoring either Clopidogrel or placebo.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09

A line graph depicting cumulative event rate percentages over 36 months of follow-up for fatal or non-fatal vascular events. Two lines represent aspirin and clopidogrel bisulfate treatments, with event rates increasing over time. The graph includes a p-value of 0.045 comparing the two groups.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10

A forest plot chart showing the hazard ratios with 95% confidence intervals comparing Clopidogrel and Aspirin use across qualifying conditions: Stroke, MI (Myocardial Infarction), PAD (Peripheral Artery Disease), and Overall. The x-axis represents the hazard ratio range from 0.6 to 1.3. Data points indicate patient numbers and event counts for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.